Clinical trials: completed, in Monaco
Rheumatoid Arthritis
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis
This study is intended to evaluate the efficacy and safety of Certolizumab Pegol (CZP) in combination with Methotrexate (MTX) for inducing and sustaining clinical response in the treatment of Disease Modifying Antirheumatic Drug…
- Trial name
- C-early (NCT01519791)
- Testing
- Certolizumab Pegol, Methotrexate
- Where
- 178 sites in United States, Argentina and 20 more
- Volunteers
- 880 people
- Sponsor
- UCB Pharma SA
Rheumatoid Arthritis
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis
This study is intended to evaluate the efficacy and safety of Certolizumab Pegol (CZP) in combination with Methotrexate (MTX) for sustaining clinical response achieved in study RA0055 Period 1 [NCT01519791].
- Trial name
- C-early (NCT01521923)
- Testing
- Certolizumab Pegol + Methotrexate (MTX)
- Where
- 178 sites in United States, Argentina and 20 more
- Volunteers
- 359 people
- Sponsor
- UCB Pharma
Neoplasms Malignant, Covid19
Thromboembolic Risk Screening in Patients With Cancer and COVID-19
Study Rational Since December 2019, outbreak of COVID-19 caused by a novel virus SARS-Cov-2 has spread rapidly around the world and became a pandemic issue.
- Conditions
- Neoplasms Malignant, Covid19, Thromboembolism
- Trial name
- NEOTHROCOVID (NCT04616846)
- Testing
- Peripheral venous ultrasound
- Where
- 6 sites in France, Monaco
- Volunteers
- 88 people
- Sponsor
- Centre Antoine Lacassagne
Paroxysmal Atrial Fibrillation
Prospective Evaluation of Open Irrigated Ablation Catheters With High Resolution Mapping to Treat Paroxysmal Atrial Fibrillation
To obtain data for the Rhythmia™ Mapping System in conjunction with Boston Scientific Open-Irrigated (OI) Catheters for ablation of Paroxysmal Atrial Fibrillation (PAF) according to current international and local guidelines.
- Trial name
- INTERRUPT AF (NCT03729830)
- Testing
- Boston Scientific Open Irrigated Ablation Catheters
- Where
- 26 sites in United States, Germany and 4 more
- Volunteers
- 415 people
- Sponsor
- Boston Scientific Corporation
Paroxysmal Atrial Fibrillation
Clinical Evaluation of the StablePoint Catheter and Force Sensing System for Paroxysmal Atrial Fibrillation
The NEwTON AF study is a multi-center, global, prospective, single arm study to establish the safety and effectiveness of the IntellaNav StablePoint Catheter and Force-Sensing System in subjects with symptomatic, drug refractory…
- Trial name
- NEwTON AF (NCT04580914)
- Testing
- Treatment with IntellaNav StablePoint Ablation Catheter
- Where
- 47 sites in United States, Austria and 11 more
- Volunteers
- 321 people
- Sponsor
- Boston Scientific Corporation
Rheumatoid Arthritis
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
The purpose of this study is to determine if abatacept is effective in the treatment of early rheumatoid arthritis.
- Trial name
- AVERT-2 (NCT02504268)
- Testing
- Abatacept, Methotrexate
- Where
- 201 sites in United States, Argentina and 29 more
- Volunteers
- 994 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
This study is conducted to evaluate the short (12 Weeks) and long term (104 Weeks) efficacy of Certolizumab Pegol compared with Adalimumab both in combination with Methotrexate (MTX) in the treatment of moderate to severe…
- Trial name
- NCT01500278
- Testing
- Certolizumab Pegol (CZP), Adalimumab (ADA), Methotrexate (MTX)
- Where
- 175 sites in United States, Australia and 18 more
- Volunteers
- 915 people
- Sponsor
- UCB Pharma SA
Rheumatoid Arthritis
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
This multicenter, prospective, observational study will assess the efficacy of MabThera/Rituxan (rituximab) and alternative TNF-inhibitors in patients with rheumatoid arthritis who are non-responders or intolerant to a single…
- Trial name
- NCT01557348
- Where
- 215 sites in Canada, Colombia and 10 more
- Volunteers
- 1,239 people
- Sponsor
- Hoffmann-La Roche
Active Rheumatoid Arthritis, Arthritis, Rheumatoid
Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis
Study to evaluate whether there is sustained remission and productivity in subjects with early rheumatoid arthritis started on etanercept plus methotrexate treatment.
- Conditions
- Active Rheumatoid Arthritis, Arthritis, Rheumatoid, Rheumatoid Arthritis
- Trial name
- NCT00913458
- Testing
- etanercept
- Where
- 59 sites in France, Germany and 11 more
- Volunteers
- 306 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Evaluation of EULAR-RAID Score in Rheumatoid Arthritis Patients
The Disease Activity Score (DAS) is a system of measurement developed in the 1980s that uses certain criteria, including joint counts and patient perceived disease activity, to measure disease activity in people with Rheumatoid…
- Trial name
- Rainbow (NCT00768053)
- Testing
- Etanercept
- Where
- 17 sites in France, Monaco
- Volunteers
- 108 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer